Published :
Tables : 43
Figures : 41
Category : Healthcare
No. of Pages : 210
Report Code : HC-U3226
Ebola Vaccines and Drugs Market Overview: In recent years, Ebola has emerged as one of the world's greatest health threats. Science has known about the Ebola virus and its disease for decades, but the risks of a global epidemic have increased exponentially since globalization. Since West Africa has recently been afflicted by Ebola, the disease has been brought to the forefront of global attention. There are several symptoms associated with Ebola, including sore throat, muscle pain, headache, and fever. The patient suffers from a viral hemorrhagic fever, which means he or she bleeds both internally and externally. By infected patients with the Ebola virus, liver and kidney function is greatly compromised. In the global market for Ebola drugs and vaccines, the lack of a reliable cure for the disease is one of the biggest driving factors, with the need for a cure being among the most urgent and lucrative. Global Ebola drugs and vaccines markets are currently driven by the lack of a foolproof solution. In spite of the development of containment and management protocols for Ebola, a cure has not yet been discovered. There is a massive unmet need for Ebola drugs and vaccines that drives the global market for them. Government support for Ebola research has made developing Ebola drugs and vaccines a profitable business for pharmaceutical companies as well. A major driver for the market in the coming years is also expected to be this factor. Research efforts have also been spurred by the unpredictable nature of Ebola since the risk of disease increases significantly without a clear understanding of its etiology and pathophysiology. In addition to medical factors, traveling between countries with more and more people is one of the most important non-medical factors affecting the global Ebola drug and vaccines market. FutureWise Market Research has instantiated a report that provides an intricate analysis of Ebola Vaccines and Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Ebola Vaccines and Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Ebola Vaccines and Drugs Market: Arbutus Biopharma GlaxoSmithKline Johnson & Johnson Services, Inc. Hemispherx Biopharma, Inc. BioCryst Pharmaceuticals, Inc. NanoViricides, Inc. NewLink Genetics Corporation Chimerix, Inc. Sarepta Therapeutics Mapp Biopharmaceutical, Inc. (Note: The list of the major players will be updated with the latest market scenario and trends) Ebola Vaccines and Drugs Market Segmentation: By Treatment • Vaccine (Under Trials) o cAd3-Zebov o rVSV-Zebov o TKMEbola o AVI-7537 o HEB o BCRX o NNVC • Drugs (Under Trials) o Brincidofovir o ZMapp o Favipiravir o Zoloft o Vascor By End User • Hospitals • Ambulatory Surgery Centres • Specialized Clinics • Army Camps (Veteran Facilities) By Region North America Europe Asia-Pacific Latin America Middle East and Africa Ebola Vaccines and Drugs Market Sample Video: Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the Ebola Vaccines and Drugs Market By Treatment, By End User and By Region. To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
In recent years, Ebola has emerged as one of the world's greatest health threats. Science has known about the Ebola virus and its disease for decades, but the risks of a global epidemic have increased exponentially since globalization. Since West Africa has recently been afflicted by Ebola, the disease has been brought to the forefront of global attention. There are several symptoms associated with Ebola, including sore throat, muscle pain, headache, and fever. The patient suffers from a viral hemorrhagic fever, which means he or she bleeds both internally and externally. By infected patients with the Ebola virus, liver and kidney function is greatly compromised. In the global market for Ebola drugs and vaccines, the lack of a reliable cure for the disease is one of the biggest driving factors, with the need for a cure being among the most urgent and lucrative. Global Ebola drugs and vaccines markets are currently driven by the lack of a foolproof solution. In spite of the development of containment and management protocols for Ebola, a cure has not yet been discovered. There is a massive unmet need for Ebola drugs and vaccines that drives the global market for them. Government support for Ebola research has made developing Ebola drugs and vaccines a profitable business for pharmaceutical companies as well. A major driver for the market in the coming years is also expected to be this factor. Research efforts have also been spurred by the unpredictable nature of Ebola since the risk of disease increases significantly without a clear understanding of its etiology and pathophysiology. In addition to medical factors, traveling between countries with more and more people is one of the most important non-medical factors affecting the global Ebola drug and vaccines market.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Ebola Vaccines and Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Ebola Vaccines and Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Ebola Vaccines and Drugs Market:
(Note: The list of the major players will be updated with the latest market scenario and trends)
Ebola Vaccines and Drugs Market Segmentation:
By Treatment
• Vaccine (Under Trials) o cAd3-Zebov o rVSV-Zebov o TKMEbola o AVI-7537 o HEB o BCRX o NNVC • Drugs (Under Trials) o Brincidofovir o ZMapp o Favipiravir o Zoloft o Vascor
By End User
• Hospitals • Ambulatory Surgery Centres • Specialized Clinics • Army Camps (Veteran Facilities)
By Region
Ebola Vaccines and Drugs Market Sample Video:
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Ebola Vaccines and Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Ebola Vaccines and Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Ebola Vaccines and Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Ebola Vaccines and Drugs Market, By Treatment Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Vaccine (Under Trials) 7.1.1. cAd3-Zebov 7.1.2. rVSV-Zebov 7.1.3. TKMEbola 7.1.4. AVI-7537 7.1.5. HEB 7.1.6. BCRX 7.1.7. NNVC 7.2. Drugs (Under Trials) 7.2.1. Brincidofovir 7.2.2. ZMapp 7.2.3. Favipiravir 7.2.4. Zoloft 7.2.5. Vascor 8. Ebola Vaccines and Drugs Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Hospitals 8.2. Ambulatory Surgery Centres 8.3. Specialized Clinics 8.4. Army Camps (Veteran Facilities) 9. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028 10. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Regional Market Trends 10.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.3.1. Brazil 10.3.2. Venezuela 10.3.3. Argentina 10.3.4. Rest of Latin America 10.4. Market Size (USD Million) Forecast for Latin America 2022-2028 11. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Switzerland 11.2.9. Rest of Western Europe 12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. Singapore 12.2.4. India 12.2.5. Australia and New Zealand 12.2.6. ASEAN 12.2.7. South Korea 12.2.8. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 13. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028 14. Market Share Analysis and Competitive Landscape 14.1. Global Landscape - Key Players, Revenue and Presence 14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 14.3. Global Emerging Companies 14.4. North America - Market Share Analysis and Key Regional Players 14.5. Europe - Market Share Analysis and Key Regional Players 14.6. Asia Pacific - Market Share Analysis and Key Regional Players 14.7. Global Key Player - Growth Matrix 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Technology Portfolio, Financial Layouts) 15.1. Arbutus Biopharma 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. GlaxoSmithKline 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Johnson & Johnson Services, Inc. 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Hemispherx Biopharma, Inc. 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5. BioCryst Pharmaceuticals, Inc. 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6. NanoViricides, Inc. 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. NewLink Genetics Corporation 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Chimerix, Inc. 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Sarepta Therapeutics 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. Mapp Biopharmaceutical, Inc. 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME key takeaway points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Ebola Vaccines and Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Ebola Vaccines and Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Ebola Vaccines and Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Ebola Vaccines and Drugs Market, By Treatment Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Vaccine (Under Trials) 7.1.1. cAd3-Zebov 7.1.2. rVSV-Zebov 7.1.3. TKMEbola 7.1.4. AVI-7537 7.1.5. HEB 7.1.6. BCRX 7.1.7. NNVC 7.2. Drugs (Under Trials) 7.2.1. Brincidofovir 7.2.2. ZMapp 7.2.3. Favipiravir 7.2.4. Zoloft 7.2.5. Vascor
8. Ebola Vaccines and Drugs Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Hospitals 8.2. Ambulatory Surgery Centres 8.3. Specialized Clinics 8.4. Army Camps (Veteran Facilities)
9. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. U.S.A 9.2.2. Canada 9.2.3. Mexico 9.3. Market Size (USD Million) Forecast for North America 2022-2028
10. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Regional Market Trends 10.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.3.1. Brazil 10.3.2. Venezuela 10.3.3. Argentina 10.3.4. Rest of Latin America 10.4. Market Size (USD Million) Forecast for Latin America 2022-2028
11. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Switzerland 11.2.9. Rest of Western Europe
12. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Japan 12.2.2. China 12.2.3. Singapore 12.2.4. India 12.2.5. Australia and New Zealand 12.2.6. ASEAN 12.2.7. South Korea 12.2.8. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
13. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. GCC 13.2.2. Israel 13.2.3. South Africa 13.2.4. Rest of MEA 13.3. Market Size (USD Million) Forecast for MEA 2022-2028
14. Market Share Analysis and Competitive Landscape 14.1. Global Landscape - Key Players, Revenue and Presence 14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 14.3. Global Emerging Companies 14.4. North America - Market Share Analysis and Key Regional Players 14.5. Europe - Market Share Analysis and Key Regional Players 14.6. Asia Pacific - Market Share Analysis and Key Regional Players 14.7. Global Key Player - Growth Matrix
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Technology Portfolio, Financial Layouts) 15.1. Arbutus Biopharma 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. GlaxoSmithKline 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Johnson & Johnson Services, Inc. 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Hemispherx Biopharma, Inc. 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5. BioCryst Pharmaceuticals, Inc. 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6. NanoViricides, Inc. 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. NewLink Genetics Corporation 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Chimerix, Inc. 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Sarepta Therapeutics 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. Mapp Biopharmaceutical, Inc. 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview
16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME key takeaway points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics